NCT06313996 2026-03-18A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 3 Withdrawn